Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Summary

This research is being done so that we can look at the safety and efficacy of deferiprone in people with sickle cell disease or other anemias. Deferiprone is a drug that removes iron from the body. We will be comparing deferiprone with deferoxamine, another drug that removes iron from the body.

Timeline

Start

2014-04-17

Primary completion

2019-04-20

Completion

2019-06-18

Outcome

Met primary endpoint

Stopped (Enrollment): “Difficulties with additional recruitment as pool of potential patients was exhausted, and sufficient information for determination of study outcome measure was already obtained”

paper with noninferiority of deferiprone to deferoxamine demonstrated by analysis of covariance (least squares mean difference 0.40 [0.56]; 96.01% confidence interval, -0.76 to 1.57). PMID 34847228 ↗

Publications

• Kwiatkowski JL, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Alshehri A, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Tricta F, Elalfy MS. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022 Feb 22;6(4):1243-1254. doi: 10.1182/bloodadvances.2021004938.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Deferiprone	Small molecule	25 mg/kg	Oral
Subject	Deferiprone	Small molecule	33 mg/kg	Oral
Comparator	Deferoxamine	Other / unclassified	20 mg/kg	Subcutaneous
Comparator	Deferoxamine	Other / unclassified	40 mg/kg	Subcutaneous
Comparator	Deferoxamine	Other / unclassified	50 mg/kg	Subcutaneous

Indications